This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Generex Biotechnology Announces Presentation Of Early Results Showing Activity Of Cancer Vaccine In Patients With Triple Negative Breast Cancer

Stocks in this article: GNBT









WORCESTER, Mass. and TORONTO, Sept. 13, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB:GNBT) ( www.generex.com), announced today presentation of early results from an efficacy study of an immunotherapeutic in triple negative breast cancer patients.  The immunotherapeutic is being developed by Antigen Express, Inc. ( www.antigenexpress.com), a wholly owned subsidiary of Generex.  The results will be presented on Friday, September 14, 2012 at the 2012 Breast Cancer Symposium organized by the American Society of Clinical Oncology (ASCO) being held in San Francisco September 13 - 15.

The presentation, entitled Early Efficacy Analysis of the AE37 Vaccine in Patients with HER2 Low-Expressing and Triple Negative Breast Cancer, will be made by Dr. Elizabeth Mittendorf, who is the Principal Investigator of the ongoing Phase II trial of the immunotherapeutic AE37.  While the study showed an overall reduction of 42% in the risk of relapse in all patients of the study who received the vaccine, the reduction in the risk of relapse was 66% in patients with low expression of the HER2 oncoprotein who were classified as having triple negative breast cancer.

The immunotherapeutic being developed by Antigen Express is designed to generate an immune response specifically targeting tumor cells expressing the HER2 oncoprotein.  While this is the same target as that of the widely used drug Herceptin, the immune response elicited by AE37 is capable destroying cells expressing lower levels of HER2 that are required for sensitivity to Herceptin.  "The suggestion of the ability of AE37 to prevent recurrence in breast cancer patients is very encouraging," said Dr. Mittendorf.  "This is particularly so in patients with triple negative disease, for whom treatment options are extremely limited," she added.

Antigen Express is currently in late stage Phase II clinical development of AE37.  Based upon positive data obtained to date, the company is proceeding with plans for a pivotal Phase III trial.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs